查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2020323

药品活性成分（API）市场规模、份额、成长及全球产业分析：按类型、应用和地区划分，并提供2026-2034年的洞察和预测

Active Pharmaceutical Ingredient (API) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 138 Pages | 商品交期: 请询问到货日

价格

活性药物成分（API）市场的成长要素

2025年全球活性药物成分（API）市值为2,452.6亿美元，预计2026年将成长至2,612.8亿美元。预计到2034年，该市场将达到4,577.5亿美元，在预测期（2026-2034年）内复合年增长率为7.26%。

受创新药物需求旺盛和慢性病盛行率上升的推动，预计到 2025 年，北美将以 47.22% 的市占率引领全球市场。

市场概览

原料药（API），也称为原料药，是药物发挥治疗作用的主要成分。它们透过化学或生物方法生产，是药物製剂的基础。

受先进治疗方法需求不断增长、个人化医疗日益受到重视以及製药和生物技术公司持续创新的推动，市场正经历稳步增长。此外，新型药物递送系统的广泛应用也进一步促进了全球原料药的需求。

新冠疫情的影响

新冠疫情初期对原料药市场造成了负面影响，尤其是在中国，工厂停工和原料供应链中断是主要原因。选择性手术需求的减少也影响了药物消费。

然而，对救命药物（尤其是呼吸系统药物）的强劲需求，以及全球生产设施的重新开放，使得疫情后市场得以復苏。

市场趋势

API生产外包增加

市场主要趋势之一是原料药生产外包给中国和印度等国家的情况日益增加。製药公司正逐步放弃内部生产，以降低成本，并更专注于药物发现和研发。

合约开发和生产组织 (CDMO) 透过提供专业知识、基础设施和扩充性，变得越来越重要，从而推动市场成长。

市场驱动因素

药品需求不断成长

癌症、心血管疾病和糖尿病等慢性疾病在全球造成的负担日益加重，显着增加了对药品的需求，从而推动了原料药市场的发展。

此外，新兴国家医疗保健支出不断增长，诊断率不断提高，导致患者群体不断扩大，进而增加了对学名药和品牌药的需求。

生物製药需求不断成长

向生物製药和生物相似药的转型也是主要的成长要素。生物製药原料药因其在治疗复杂疾病方面的有效性、监管核准的增加以及生物技术的创新而备受关注。

市场限制因素

价格波动和监管挑战

新兴市场定价政策的不确定性以及对有限原料供应商的依赖会阻碍市场成长。价格快速上涨和供应链中断给製造商带来挑战。

此外，各地区严格的监管要求使得原料药的生产和核准过程变得复杂且耗时。

細項分析

按类型

到 2026 年，在强大的研发投入和高效药物创新推动下，品牌 API 市场将占据主导地位，市占率达到 62.10%。

然而，由于专利到期和对经济实惠的药品的需求不断增长，非专利药原料药市场预计将快速成长。

透过合成方法

到 2026 年，合成 API 领域将凭藉其低廉的製造成本和简单的製造工艺，以 70.52% 的市占率引领市场。

另一方面，随着对先进生物製药的需求不断增长，生物製剂原料药预计将以更快的速度成长。

区域洞察

北美洲

预计北美市场规模将在2025年达到1,158.1亿美元，2026年达到1,227.4亿美元。这一增长是由慢性病的高发病率和对研发的大力投入所推动的。

欧洲

预计到 2025 年，欧洲的市场规模将达到 567.8 亿美元，到 2026 年将达到 606.1 亿美元，这得益于药品生产和研发倡议的增加。

亚太地区

预计亚太地区2025年市场规模将达533.5亿美元，2026年将成长至573.1亿美元。该地区成长速度最快，这得益于其低廉的製造成本和强劲的外包趋势。

世界其他地区

预计到 2025 年，该地区的价值将达到 193.2 亿美元，到 2026 年将达到 206.1 亿美元，这主要得益于基础设施的改善和监管的进步。

儘管面临价格波动和监管复杂性等挑战，但外包、技术进步和新兴经济体的成长为市场带来了巨大的机会。向生物製药和个人化医疗的转型将进一步塑造原料药产业的未来，并成为全球医疗保健发展的重要支柱。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 主要慢性病盛行率：依主要国家划分，2025 年
  • 关键产业趋势—联盟、合併与收购
  • 各种活性成分的治疗用途
  • 新冠疫情对市场的影响

第五章：2021-2034年全球活性药物成分（API）市场分析、洞察与预测

  • 市场分析、洞察与预测：按类型
    • 非专利API
    • 品牌 API
  • 市场分析、洞察与预测：综合分析
    • 生物来源药物成分
    • 合成原料药
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 世界其他地区

第六章：北美活性药物成分（API）市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲活性药物成分（API）市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区活性药物成分（API）市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：2021-2034年其他地区活性药物成分（API）全球市场分析、洞察与预测

第十章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Teva Pharmaceutical Industries Ltd
    • AbbVie Inc.
    • Abbott
    • Aurobindo Pharma
    • Cipla Inc.
    • Dr. Reddy's Laboratories Ltd
    • Sun Pharmaceutical Industries Ltd
    • Amgen Inc.
    • Biocon
    • Mylan NV
Product Code: FBI102656

Growth Factors of Active Pharmaceutical Ingredient (API) Market

The global Active Pharmaceutical Ingredient (API) market was valued at USD 245.26 billion in 2025 and is projected to grow to USD 261.28 billion in 2026. The market is expected to reach USD 457.75 billion by 2034, exhibiting a CAGR of 7.26% during the forecast period (2026-2034).

North America dominated the global market with a 47.22% share in 2025, driven by high demand for innovative drugs and increasing prevalence of chronic diseases.

Market Overview

Active Pharmaceutical Ingredients (APIs), also known as bulk drugs, are the key components responsible for the therapeutic effects of medicines. They are produced through chemical or biological processes and form the backbone of pharmaceutical formulations.

The market is witnessing steady growth due to rising demand for advanced therapeutics, increasing focus on personalized medicine, and continuous innovations by pharmaceutical and biotechnology companies. Additionally, the growing adoption of novel drug delivery systems is further strengthening the demand for APIs globally.

Impact of COVID-19

The COVID-19 pandemic had a negative impact on the API market initially due to factory shutdowns, especially in China, and disruptions in raw material supply chains. Reduced demand for elective procedures also affected pharmaceutical consumption.

However, the market rebounded post-pandemic due to strong demand for life-saving drugs, particularly respiratory medicines, and the reopening of manufacturing facilities worldwide.

Market Trends

Rising Outsourcing of API Manufacturing

One of the key trends in the market is the increasing outsourcing of API production to countries such as China and India. Pharmaceutical companies are shifting away from in-house manufacturing to reduce costs and focus more on drug discovery and development.

Contract Development and Manufacturing Organizations (CDMOs) are gaining importance as they offer specialized expertise, infrastructure, and scalability, thereby boosting market growth.

Market Drivers

Growing Demand for Pharmaceuticals

The rising global burden of chronic diseases such as cancer, cardiovascular disorders, and diabetes is significantly increasing the demand for pharmaceutical drugs, thereby driving the API market.

In addition, growing healthcare expenditure and improved diagnosis rates in emerging economies are expanding the patient pool, leading to higher demand for both generic and branded drugs.

Increasing Demand for Biologics

The shift toward biologics and biosimilars is another major growth driver. Biological APIs are gaining traction due to their effectiveness in treating complex diseases, supported by increasing regulatory approvals and innovation in biotechnology.

Market Restraints

Price Fluctuations and Regulatory Challenges

Unpredictable pricing policies in emerging markets and dependency on limited suppliers for raw materials can hinder market growth. Sudden price hikes and supply chain disruptions pose challenges for manufacturers.

Additionally, stringent regulatory requirements across different regions make API production and approvals complex and time-consuming.

Segmentation Analysis

By Type

The branded API segment dominated the market with a 62.10% share in 2026, driven by strong R&D investments and innovation in high-potency drugs.

However, the generic API segment is expected to grow rapidly due to patent expirations and increasing demand for cost-effective medicines.

By Synthesis

The synthetic API segment led the market with a 70.52% share in 2026, owing to lower production costs and simpler manufacturing processes.

Meanwhile, biological APIs are projected to grow at a faster rate due to rising demand for advanced biologic therapies.

Regional Insights

North America

North America generated USD 115.81 billion in 2025 and is expected to reach USD 122.74 billion in 2026. Growth is driven by high prevalence of chronic diseases and strong R&D investments.

Europe

Europe accounted for USD 56.78 billion in 2025 and is projected to reach USD 60.61 billion in 2026, supported by increasing pharmaceutical production and research initiatives.

Asia Pacific

Asia Pacific held USD 53.35 billion in 2025 and is expected to grow to USD 57.31 billion in 2026. The region is the fastest-growing due to low manufacturing costs and strong outsourcing trends.

Rest of the World

This region was valued at USD 19.32 billion in 2025 and is projected to reach USD 20.61 billion in 2026, driven by improving infrastructure and regulatory developments.

Competitive Landscape

The API market is highly fragmented with key players such as AbbVie Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Amgen Inc., Cipla Inc., and Sun Pharmaceutical Industries Ltd.

These companies focus on strategic partnerships, acquisitions, and expansion of manufacturing capabilities to strengthen their global presence.

Conclusion

In conclusion, the global API market is set for steady and sustained growth, rising from USD 245.26 billion in 2025 to USD 457.75 billion by 2034. The growth is primarily driven by increasing demand for pharmaceuticals, rising chronic disease burden, and expanding biologics segment.

Despite challenges such as pricing volatility and regulatory complexities, the market presents strong opportunities through outsourcing, technological advancements, and growth in emerging economies. The shift toward biologics and personalized medicine will further shape the future of the API industry, making it a critical pillar of global healthcare development.

Segmentation

By Type

  • Generic API
  • Branded API

By Synthesis

  • Biological API
  • Synthetic API

By Geography

  • North America (By Type, By Synthesis, and By Country)
    • U.S.
    • Canada
  • Europe (By Type, By Synthesis, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, By Synthesis, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Rest of World (By Type, and By Synthesis)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Chronic Diseases, By Key Countries/Regions, 2025
  • 4.2. Key Industry Developments - Partnerships, Mergers, And Acquisitions
  • 4.3. Therapeutic Applications of the Different Types of Active Pharmaceutical Ingredient
  • 4.4. Impact of COVID-19 on the Market

5. Global Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Generic API
    • 5.1.2. Branded API
  • 5.2. Market Analysis, Insights and Forecast - By Synthesis
    • 5.2.1. Biological API
    • 5.2.2. Synthetic API
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Rest of World

6. North America Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Generic API
    • 6.1.2. Branded API
  • 6.2. Market Analysis, Insights and Forecast - By Synthesis
    • 6.2.1. Biological API
    • 6.2.2. Synthetic API
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Generic API
    • 7.1.2. Branded API
  • 7.2. Market Analysis, Insights and Forecast - By Synthesis
    • 7.2.1. Biological API
    • 7.2.2. Synthetic API
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Generic API
    • 8.1.2. Branded API
  • 8.2. Market Analysis, Insights and Forecast - By Synthesis
    • 8.2.1. Biological API
    • 8.2.2. Synthetic API
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Rest of World Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Generic API
    • 9.1.2. Branded API
  • 9.2. Market Analysis, Insights and Forecast - By Synthesis
    • 9.2.1. Biological API
    • 9.2.2. Synthetic API

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Teva Pharmaceutical Industries Ltd
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & Services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. AbbVie Inc.
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & Services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Abbott
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & Services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Aurobindo Pharma
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & Services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Cipla Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & Services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Dr. Reddy's Laboratories Ltd
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & Services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Sun Pharmaceutical Industries Ltd
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & Services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Amgen Inc.
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & Services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Biocon
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & Services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. Mylan N.V.
      • 10.2.10.1. Overview
      • 10.2.10.2. Products & Services
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034
  • Table 3: Global Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 4: North America Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 5: North America Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034
  • Table 6: North America Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 7: Europe Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: Europe Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034
  • Table 9: Europe Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 11: Asia Pacific Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034
  • Table 12: Asia Pacific Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Rest of World Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Rest of World Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034

List of Figures

  • Figure 01: Global Active Pharmaceutical Ingredient Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
  • Figure 02: Global Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2026 & 2034
  • Figure 03: Global Active Pharmaceutical Ingredient Market Value Share (%), By Synthesis, 2026 & 2034
  • Figure 04: Global Active Pharmaceutical Ingredient Market Value (USD billion), By Region, 2026 & 2034
  • Figure 05: North America Active Pharmaceutical Ingredient Market Value (USD billion), By Type, 2026 & 2034
  • Figure 06: North America Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2025
  • Figure 07: North America Active Pharmaceutical Ingredient Market Value (USD billion), By Synthesis, 2026 & 2034
  • Figure 08: North America Active Pharmaceutical Ingredient Market Value Share (%), By Synthesis, 2025
  • Figure 09: North America Active Pharmaceutical Ingredient Market Value (USD billion), By Country, 2026 & 2034
  • Figure 10: North America Active Pharmaceutical Ingredient Market Value Share (%), By Country, 2025
  • Figure 11: Europe Active Pharmaceutical Ingredient Market Value (USD billion), By Type, 2026 & 2034
  • Figure 12: Europe Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2025
  • Figure 13: Europe Active Pharmaceutical Ingredient Market Value (USD billion), By Synthesis, 2026 & 2034
  • Figure 14: Europe Active Pharmaceutical Ingredient Market Value Share (%), By Synthesis, 2025
  • Figure 15: Europe Active Pharmaceutical Ingredient Market Value (USD billion), By Country/Sub-Region, 2026 & 2034
  • Figure 16: Europe Active Pharmaceutical Ingredient Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 17: Asia Pacific Active Pharmaceutical Ingredient Market Value (USD billion), By Type, 2026 & 2034
  • Figure 18: Asia Pacific Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2025
  • Figure 19: Asia Pacific Active Pharmaceutical Ingredient Market Value (USD billion), By Synthesis, 2026 & 2034
  • Figure 20: Asia Pacific Active Pharmaceutical Ingredient Market Value Share (%), By Synthesis, 2025
  • Figure 21: Asia Pacific Active Pharmaceutical Ingredient Market Value (USD billion), By Country/Sub-Region, 2026 & 2034
  • Figure 22: Asia Pacific Active Pharmaceutical Ingredient Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 23: Rest of World Active Pharmaceutical Ingredient Market Value (USD billion), By Type, 2026 & 2034
  • Figure 24: Rest of World Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2025
  • Figure 25: Rest of World Active Pharmaceutical Ingredient Market Value (USD billion), By Synthesis, 2026 & 2034
  • Figure 26: Rest of World Active Pharmaceutical Ingredient Market Value (USD %), By Synthesis 2025
  • Figure 27: Global Active Pharmaceutical Ingredient Market Share (%), by Company, 2025